the results of studies into the effects of an anti-IL-1 strategy on cartilage damage in animal models of OA are also puzzling. Careful examination of studies in animal models of OA (anterior cruciate ligament injury in pigs, meniscectomy in mice or intra-articular injection of collagenase in mice) indicates that, compared with placebo, IL-1β inhibition might induce different effects on cartilage destruction depending on the type of disease induction used. For the most part, IL-1β inhibition positively decreased the extent of cartilage lesions, but had no effect in a mouse model of inflammatory collagenaseinduced OA 6 and had a detrimental effect in an IL-1β-deficient mouse 7 .
Several hypotheses might help us to understand the failure of anti-IL-1 therapy in human trials of knee OA. The route of administration is an important consideration given the difficulty of reaching cartilage tissue devoid of vascularization, so intra-articular administration of any molecule should be considered. New strategies such as gene therapy might help to increase the intra-articular residence time of delivered drugs, but other considerations should also be taken into account. The concentration of IL-1 in the synovial fluid of patients with OA is low or undetectable, and the IL-1Ra:IL-1 ratio is high, suggesting that IL-1 is already neutralized in the synovial fluid 8 . In advanced disease, the contribution of IL-1 might be weak and part of a complex network of different pro-inflammatory mediators 4 . As a consequence, the blockade of a single cytokine at this stage of the disease is unlikely to affect disease progression and clinical response.
Thus, if we may rethink the anti-IL-1 strategy while still considering synovitis as the main target, several situations present themselves in which IL-1 inhibition might be useful. Intervention at an early stage of the disease could be a window of opportunity, especially when synovitis is present and the extent of cartilage lesions is limited. IL-1 is involved in the transmission of pain through its pro-inflammatory function 4 and IL-1 inhibition in pre-OA conditions, such as post-traumatic injury of the knee, has shown some beneficial effects on pain and on recurrence of knee swelling 9 . Anti-IL-1 strategies could also be considered for patients with comorbidities that involve systemic inflammation. Thus, in the Canakinumab Antiinflammatory Thrombosis Outcome Study
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(CANTOS), in which repeated subcutaneous injection of canakinumab (an anti-IL-1β antibody) was compared with placebo in patients with a history of myocardial infarction, the anti-inflammatory effect of IL-1 inhibition reduced not only cardiovascular events but also the incidence of total knee or hip replacement as a result of OA, as well as OA-related adverse events, over a median follow-up of 3.7 years 10 . Overall, we have learned from the lutikizumab trial 1 that IL-1 inhibition is not effective for standard knee OA, even in the presence of synovitis. This result does not mean that the concept of IL-1 inhibition in OA is completely dead. This strategy could still be considered, either for a short period of time in early OA or when synovial inflammation is severe, or as a long-term treatment when systemic inflammation is substantial. 
N e w s & V i e w s
In a new randomized controlled trial, WedellNeergaard et al.
1 investigated the effects of IL-6 inhibition on exercise-induced changes in visceral adipose tissue mass. They treated abdominally obese adults with either tocilizumab (an anti-IL-6 receptor monoclonal antibody) or placebo as well as either a 12-week aerobic (bicycle) exercise regimen or no exercise. Visceral adiposity was reduced only in the placebo group who were performing the exercise regimen, suggesting that IL-6 signalling is necessary for exercise-mediated reduction of visceral fat. This interesting finding is potentially important for the management of patients with rheumatoid arthritis (RA).
The important role of IL-6 in the pathophysiology of RA is well-established 2 . This pleiotropic cytokine is produced by many cell types, including monocytes, T cells, B cells, fibroblasts, osteoblasts and endothelial cells. Serum and synovial fluid concentrations of IL-6 in patients with RA are high and correlate with disease activity and joint destruction. IL-6 is involved in a number of pathways that can contribute to pathogenesis of RA, including T cell differentiation, proliferation and volume 15 | april 2019 | 193 Nature reviews | RhEumatoLogy N e w s & V i e w s apoptosis; B cell maturation and autoantibody production; neutrophil migration; osteoclast maturation; and pannus proliferation. IL-6 is also the primary driver of systemic manifestations of RA, such as the acute phase response, anaemia, fatigue, fever and muscle weakness. This pivotal function of IL-6 has been confirmed in the 'clinical arena' , as multiple controlled clinical trials and long-term observational studies have shown that inhibition of IL-6 reduces inflammatory disease activity, improves physical function and decelerates the progression of radiological joint damage.
IL-6 is also involved in energy metabolism and is produced by skeletal muscle, especially in response to repetitive muscle contraction 3 . Initially thought to be secreted as a result of muscle damage, IL-6 is now known to be released as a response to muscle glycogen depletion and seems to participate in glucose homeostasis and lipolysis 3 . In particular, IL-6 seems to enhance visceral adipose tissue lipolysis, as indicated by the new study from WedellNeergaard et al.
1
. Notably, these positive effects of IL-6 and other myokines are usually associated with their transient production and shortterm action 4 . The effects of chroni cally elevated IL-6 (as in the case of patients with RA) on metabolism have not yet been investigated.
Control of body weight and improvement of body composition are particularly important in the overall management of RA because such abnormalities are common in these patients and are associated with disease outcomes, including a well-established increase in cardiometabolic risk 5 . The role of exercise in achieving these targets is increasingly being recognized 6 . Many patients with RA present with altered body composition, often with reduced lean body mass in the presence of unaltered or slightly elevated weight, a condition termed rheumatoid cachexia 7 . Rheumatoid cachexia is associated with worse RA disease outcomes, increased disability and reduced quality of life. Counterintuitively, being overweight or obese is also common in RA populations today. Obesity is not only a risk factor for the development of RA, but is also associated with worse disease outcomes and poor response to DMARDs, including some biologic agents 8 , but not to tocilizumab; this finding led to some speculation that tocilizumab might actually be a good choice for obese patients with RA 9 . In this respect, the findings of Wedell-Neergaard et al.
, that IL-6 inhibition might attenuate the beneficial effects of exercise on visceral adiposity, are important as they argue against IL-6 inhibition being a good therapeutic choice in overweight or obese patients with RA.
To date, only one study has investigated IL-6 inhibition in relation to body composition in RA 10 . Tournadre et al. 10 showed that after 12 months of treatment with tocilizumab, patient weight and lean body mass were slightly increased. Interestingly, although total fat mass was unchanged in these patients, a change in fat distribution was reported, with truncal to peripheral fat ratio decreasing substantially (that is, relatively more fat was stored in the periphery). These results seem to indicate a beneficial effect of inhibiting IL-6 signalling; however, the lack of an alternative treatment control group and absence of an exer cise intervention in this study limits our ability to compare and interpret these findings relative to the findings of Wedell-Neergaard et al.
. Nevertheless, some potentially 'telling' differences between these studies might enlighten us.
Wedell-Neergaard et al. 1 investigated people with obesity in a low-grade inflammatory state, whereas Tournadre et al. 10 investigated patients with RA exhibiting chronic highgrade inflammation with elevated levels of IL-6 and IL-6 receptor (IL-6R) expression. Even during targeted inhibition, IL-6 and IL-6R expression can remain high in patients with RA compared with healthy individuals, and this high expression might enable some IL-6-mediated effects to be maintained in some tissues. The slightly increased lean body mass after IL-6 inhibition in patients with RA reported by Tournadre et al. 10 is also an interesting finding that might indicate that adequate levels of IL-6 for muscle regeneration might persist in these patients even after therapy with an IL-6 inhibitor. IL-6 has a positive effect on the proliferative capacity of muscle stem cells, inducing muscle adaptation and regeneration 4 . Unfortunately neither study reported the post-treatment levels of IL-6 or IL-6R expression in blood or other relevant tissues such as muscle or fat.
Both studies were mostly of female participants, but the patients included in Tournadre et al. 10 were mostly of normal weight, whereas obese individuals were the focus of Wedell-Neergaard et al.
1 This difference might indicate that further mechanisms might exist that involve total body adiposity, adipocyte size or other factors. Moreover, the duration of the two studies was different, with the Tournadre et al. 10 study lasting 12 months and Wedell-Neergaard et al.
1 only 12 weeks. Perhaps short-term versus long-term IL-6 inhibition differentially affects mechanisms of lipolysis and energy metabolism, something that has not been assessed in any population.
In conclusion, Wedell-Neergaard et al. 1 contribute to our understanding of the mechanisms by which exercise can mediate abdominal fat loss in otherwise healthy but obese people. However, limited information exists regarding such mechanisms in the context of chronic inflammatory conditions such as RA, in which IL-6 is a major therapeutic target (Fig. 1) . Given the importance of adiposity and body composition in RA disease progression and outcome, more research is needed to understand the interaction between pharmacological and lifestyle interventions in this population. Systemic lupus erythematosus (SLE) is a complex autoimmune disease with a wide spectrum of manifestations (any part of the body can be affected) and variable course in which symptoms can get worse or improve, sometimes without treatment. This variability makes assessment and quantification of disease activity difficult. The primary endpoint for SLE clinical trials usually involves a combination of three disease activity instruments: SLE Disease Activity Index (SLEDAI) 1 , British Isles Lupus Activity Group (BILAG) 2 and SELENA SLEDAI Physician Global Assessment (PGA)
1 . Each has pitfalls that could potentially be addressed by newer instruments 3 (Table 1) .
A recent publication by Jesus et al. 4 highlights the widespread belief that disease heterogeneity and shortcomings of current trial endpoints have led to a crisis in SLE management 5 and that improved metrics for treatment response are long overdue. In the past three decades, late-phase (II b and III) clinical development programs involving more than 40 new treatments have failed 6 . We and others have designed and tested several novel disease activity measures, including the Lupus Foundation of America Rapid cardiopulmonary and gastrointestinal manifestations are missing. The BILAG includes 97 items, but scoring is limited to 9 integrated organ grades. Although symptoms within each organ are rated individually, BILAG counts only one organ score to reflect the single most severe grade achieved. The scoring does not increase when there are ≥2 equally severe descriptors within an organ. The SLE-DAS expands important features missed by the SLEDAI (outlined above), but it also compresses multiple symptoms into one score (for example, cardiopulmonary). The LFA-REAL individually grades each active SLE feature by current severity while maintaining simplicity of the instrument and avoiding complex weighting schemes.
The SLEDAI cannot capture partial improve ment or deterioration in alreadyactive symptoms. The SLE-DAS can capture partial changes in swollen joints, proteinuria, thrombocytopenia, and leukopenia but not in the 13 other features. It also does not take into account the severity of individual manifestations: for example, all rashes score the same. The SRI-50 and BILAG account for some change in symptom severity, but only within limited, preset definitions. The LFA-REAL has progression of symptoms built into its scoring, providing a sensitive record of deterioration or improvement over the entire range of symptom changes, avoiding the pitfalls of preset thresholds for detection.
The SLEDAI is relatively easy to use while the BILAG has more complex rules and requires extensive training. SLE-DAS resembles SLEDAI in ease of use, but some understanding of the complex weighting might be required to interpret it. The LFA-REAL has simple, intuitive, linear scaling and is very easy to interpret.
The SLE-DAS was developed utilizing rigorous psychometric methodology and clinical testing in a separate derivation and validation cohort and is, in part, weighted by prospectively collected clinical data. However, the standard for clinically meaningful improvement and worsening is a small (±0.3) PGA change with no explanation for its basis. The sensitivity of SLE-DAS to changes in PGA seems greater than SLEDAI, but this sensitivity has not been tested against the BILAG, which is the most sensitive of the established instruments. Furthermore, a more sensitive instrument will not always provide the best discrimination between Evaluation of Activity in Lupus (LFA-REAL) 7 and the SLEDAI 2000 Responder Index 50 (SRI-50) 8 ; Jesus et al. 4 have now derived and provided preliminary validation for the SLE Disease Activity Score (SLE-DAS).
The SLE-DAS was derived by evaluating 324 patients for several SLEDAI descriptors and additional clinical and laboratory features deemed important by the authors. Multivariate linear regression analysis was applied using the PGA as a dependent variable to provide a weighting system. The final SLE-DAS includes 17 items. In a validation cohort (n = 196 patients) SLE-DAS was correlated with PGA (r = 0.875) and SLEDAI-2K (r = 0.943). It was also tested for clinically meaningful change in disease activity (Δ = 1.72) and accuracy in predicting damage accrual. The authors conclude that SLE-DAS has good construct validity and better performance than SLEDAI-2K in identifying clini cally significant changes in disease activity and predicting damage. This effect could be due to improvements in the weighting system, increased mucocutaneous features, or continuous scoring of some features (arthritis, proteinuria, platelets and leukocytes) 4 . The SLEDAI is limited in the features it captures as myositis, haemolytic anaemia,
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New disease activity measures are needed for systemic lupus erythematosus (SLE). Is the new SLE-DAS better than existing measures or are other instruments, or combined scoring methods, required to manage the spectrum of SLE?
